Cargando…

Multiple Sclerosis, Disease-Modifying Therapies, and Infections

BACKGROUND AND OBJECTIVES: The use of highly effective multiple sclerosis (MS) disease-modifying therapies (DMTs) is rapidly increasing. Yet, little is known about their real-world risks of infections. The goals of this study were to assess the comparative risk of outpatient and serious infections a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langer-Gould, Annette M., Smith, Jessica B., Gonzales, Edlin G., Piehl, Fredrik, Li, Bonnie H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574822/ https://www.ncbi.nlm.nih.gov/pubmed/37813594 http://dx.doi.org/10.1212/NXI.0000000000200164

Ejemplares similares

Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis
por: Smith, Jessica B., et al.
Publicado: (2022)

Racial and Ethnic Disparities in Multiple Sclerosis Prevalence
por: Langer-Gould, Annette M., et al.
Publicado: (2022)

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations
por: Alping, Peter, et al.
Publicado: (2019)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Risk of depression in multiple sclerosis across disease-modifying therapies
por: Longinetti, Elisa, et al.
Publicado: (2021)

Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis
por: Langer-Gould, Annette, et al.
Publicado: (2018)

Multiple sclerosis, disease-modifying drugs and risk for adverse perinatal and pregnancy outcomes: Results from a population-based cohort study
por: Fink, Katharina, et al.
Publicado: (2023)

Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden
por: McKay, Kyla A., et al.
Publicado: (2021)

Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level
por: Langer‐Gould, Annette, et al.
Publicado: (2022)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

The Multiple Sclerosis Treatment Optimization Program
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

MS Sunshine Study: Sun Exposure But Not Vitamin D Is Associated with Multiple Sclerosis Risk in Blacks and Hispanics
por: Langer-Gould, Annette, et al.
Publicado: (2018)

Infections among individuals with multiple sclerosis, Alzheimer’s disease and Parkinson’s disease
por: Hu, Yihan, et al.
Publicado: (2023)

Rituximab, MS, and pregnancy
por: Smith, Jessica B., et al.
Publicado: (2020)

Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies
por: McFaul, Derek, et al.
Publicado: (2021)

Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
por: Piehl, F.
Publicado: (2020)

Risk of serious infections in multiple sclerosis patients by disease course and disability status: Results from a Swedish register-based study
por: Brand, Judith S., et al.
Publicado: (2022)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility
por: Hellwig, Kerstin, et al.
Publicado: (2016)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis
por: Simonsen, Cecilia Smith, et al.
Publicado: (2016)

Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies
por: Smith, Tyler Ellis, et al.
Publicado: (2021)

Pregnancy does not modify the risk of MS in genetically susceptible women
por: Adams, Cameron J., et al.
Publicado: (2020)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2023)

Creatinine and C-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease
por: Cui, Can, et al.
Publicado: (2020)

Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2022)

Improving quality, affordability, and equity of multiple sclerosis care
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis
por: Brusini, Irene, et al.
Publicado: (2022)

Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry
por: Chi, Calvin, et al.
Publicado: (2019)

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
por: Schweitzer, F., et al.
Publicado: (2020)

New oral disease-modifying therapies for multiple sclerosis
por: Bagert, Bridget A, et al.
Publicado: (2009)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Disease-modifying therapies in multiple sclerosis in Latin America
por: Skromne-Eisenberg, Eli, et al.
Publicado: (2017)

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
por: Jalkh, Georges, et al.
Publicado: (2020)

Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
por: Porwal, Mokshal H., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qiq241k23i1iqdss9p1hbvh3dt